Close Menu

The Scan

Moderna to Seek EUA

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

To Spot it Earlier

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Limited Trust

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Price for Open

Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.

Change for Spread

An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.

Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.

In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.

EUA Now Sought

Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.

Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.

The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.

In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.

Chicago Sewage Search

Chicago plans to test sewage there for SARS-CoV-2 infections, the Chicago Tribune reports.

Home Swabbin'

The US Food and Drug Administration has granted an Emergency Use Authorization for a rapid, at-home COVID-19 test.

A survey analysis finds men in same-sex relationships are 12 percent less likely to have a college degree in a STEM field.

In Nature this week: integration of large double-stranded DNA viruses into host genomes, more.

An updated analysis finds the SARS-CoV-2 vaccine from Pfizer and BioNTech to have a 95 percent efficacy.

Pages

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.